Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Gabapentin is indicated for the management of Postherpetic Neuraligia
The registered capital of the newly founded company is € 50 million
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The new campus has been designed as an employee-centred experience and ecosystem zone
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
An accomplished R&D leader and champion of the application of AI to drug discovery
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
